Back to Search
HOLLY BAYS, MD
MD
Family Medicine Physician
NPI: 1457462756IndividualAccepts Medicare
Specialties, Licenses & Credentials
Family Medicine PhysicianPrimary
Family Medicine
Code: 207Q00000X
MD00036495(WA)
CMS Specialties
PrimaryFAMILY PRACTICE
Education
UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE
Class of 1996
Research & Publications (20)
Review of ARBITER 2: extended-release niacin added to statin therapy slows the progression of atherosclerosis. Commentary.
PMID 19332979·Postgrad Med·2009
8-other
From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus.
PMID 19232040·Curr Med Res Opin·2009
6-review
Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients.
PMID 19243712·Clin Ther·2009
8-other
Addressing lipid treatment targets beyond cholesterol: a role for prescription omega-3 fatty acid therapy.
PMID 19279539·South Med J·2009
6-review
Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia.
PMID 19195513·Am J Cardiol·2009
4-observational
Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects.
PMID 19597368·J Cardiovasc Pharmacol·2009
4-observational
Rationale for prescription omega-3-acid ethyl ester therapy for hypertriglyceridemia: a primer for clinicians.
PMID 18536782·Drugs Today (Barc)·2008
7-preclinical
Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors.
PMID 19031552·Cardiol Clin·2008
6-review
Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
PMID 19166443·Int J Clin Pract·2008
4-observational
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.
PMID 18783301·Clin Drug Investig·2008
3-trial
Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects.
PMID 18852398·Arch Intern Med·2008
4-observational
Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease.
PMID 19026302·Am J Cardiol·2008
4-observational
Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease.
PMID 19026303·Am J Cardiol·2008
4-observational
Long-term (48-week) safety of ezetimibe 10 mg/day coadministered with simvastatin compared to simvastatin alone in patients with primary hypercholesterolemia.
PMID 18782465·Curr Med Res Opin·2008
4-observational
Measuring flushing symptoms with extended-release niacin using the flushing symptom questionnaire: results from a randomised placebo-controlled clinical trial.
PMID 18410350·Int J Clin Pract·2008
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 125 16TH AVE E
SEATTLE, WA 98112 - Phone
- (206) 326-3000
Quick Facts
- NPI
- 1457462756
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 30
- Publications
- 20
Are you this provider?
Claim Your Profile